Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24969062 | 1.00 | MAOB (0.44) | MAOBROCK2RPS6KB1TGM2EGFR | |
| SCHEMBL30152250 | 0.81 | TGM2 (0.42) | TGM2EGFRITK | |
| SCHEMBL24968851 | 0.81 | TGM2 (0.42) | TGM2EGFRITK | |
| SCHEMBL24969061 | 0.81 | EGFR (0.44) | TGM2EGFRMAPTBTK | |
| SCHEMBL24969059 | 0.78 | EGFR (0.42) | TGM2EGFRITKBTK | |
| SCHEMBL24968466 | 0.78 | CYP19A1 (0.57) | TGM2EGFR | |
| SCHEMBL30152236 | 0.73 | NISCH (0.43) | MAOBROCK2HDAC1HDAC2 | |
| SCHEMBL24969071 | 0.73 | NISCH (0.43) | MAOBROCK2HDAC1HDAC2 | |
| SCHEMBL30702607 | 0.72 | NISCH (0.49) | ROCK2 | |
| SCHEMBL28521235 | 0.68 | TGM2 (0.47) | TGM2EGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |